Login
Toggle sidebar

Lint: european-thyroid-association-tirads

european-thyroid-association-tirads
Strong List Colon Position
error

"EU-TIRADS 1: no nodule"

Line 33:8 · When enboldening an intro, the colon should not be bold. '<strong>EU-TIRADS 1: </strong>no'

"EU-TIRADS 2: benign"

Line 34:8 · When enboldening an intro, the colon should not be bold. '<strong>EU-TIRADS 2:</strong> benign'

"EU-TIRADS 3: low risk (oval, smooth margin, iso / hyperechoic, no high risk features)"

Line 35:8 · When enboldening an intro, the colon should not be bold. '<strong>EU-TIRADS 3:</strong> low'

"EU-TIRADS 4: intermediate risk (oval, smooth margin, mildly hypoechoic, no high risk features)"

Line 36:8 · When enboldening an intro, the colon should not be bold. '<strong>EU-TIRADS 4:</strong> intermediate'

"EU-TIRADS 5: any high risk features (non-oval, irregular margin, microcalcifications, marked hypoechogenicity)"

Line 37:8 · When enboldening an intro, the colon should not be bold. '<strong>EU-TIRADS 5:</strong> any'

"EU-TIRADS 2: no FNA required (unless for theraputic purpose / relieve compression)"

Line 41:8 · When enboldening an intro, the colon should not be bold. '<strong>EU-TIRADS 2:</strong> no'

"EU-TIRADS 3: >20 mm FNA"

Line 42:8 · When enboldening an intro, the colon should not be bold. '<strong>EU-TIRADS 3:</strong> '

"EU-TIRADS 4: >15 mm FNA"

Line 43:8 · When enboldening an intro, the colon should not be bold. '<strong>EU-TIRADS 4:</strong> '

"EU-TIRADS 5: >10 mm FNA,"

Line 44:8 · When enboldening an intro, the colon should not be bold. '<strong>EU-TIRADS 5:</strong> '

"EU-TIRADS 1: n/a"

Line 49:8 · When enboldening an intro, the colon should not be bold. '<strong>EU-TIRADS 1: </strong>n'

"EU-TIRADS 2: 0%"

Line 50:8 · When enboldening an intro, the colon should not be bold. '<strong>EU-TIRADS 2:</strong> 0'

"EU-TIRADS 3: low risk (2-4%)"

Line 51:8 · When enboldening an intro, the colon should not be bold. '<strong>EU-TIRADS 3:</strong> low'

"EU-TIRADS 4: intermediate risk (6-17%)"

Line 52:8 · When enboldening an intro, the colon should not be bold. '<strong>EU-TIRADS 4:</strong> intermediate'

"EU-TIRADS 5: high risk (26-87%)"

Line 53:8 · When enboldening an intro, the colon should not be bold. '<strong>EU-TIRADS 5:</strong> high'
Acronyms
warning

"EU-TIRADS is a reporting system designed by the European Thyroid Association for ultrasound assessment of thyroid nodules and stratification of requirement for FNA and malignancy. This system was based on an established French system, with validated results 2,3."

Line 1:12 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS is a reporting system designed by the European Thyroid Association for ultrasound assessment of thyroid nodules and stratification of requirement for FNA and malignancy. This system was based on an established French system, with validated results 2,3."

Line 1:181 · 'FNA' has no definition. Spell it out if it's unfamiliar to the audience.

"Assessment of the following features as well as size, location and number of nodules are recommended in the reporting of EU-TIRADS:"

Line 4:125 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 1: no nodule"

Line 33:16 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 2: benign"

Line 34:16 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 3: low risk (oval, smooth margin, iso / hyperechoic, no high risk features)"

Line 35:16 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 4: intermediate risk (oval, smooth margin, mildly hypoechoic, no high risk features)"

Line 36:16 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 5: any high risk features (non-oval, irregular margin, microcalcifications, marked hypoechogenicity)"

Line 37:16 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 2: no FNA required (unless for theraputic purpose / relieve compression)"

Line 41:16 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 2: no FNA required (unless for theraputic purpose / relieve compression)"

Line 41:41 · 'FNA' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 3: >20 mm FNA"

Line 42:16 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 3: >20 mm FNA"

Line 42:45 · 'FNA' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 4: >15 mm FNA"

Line 43:16 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 4: >15 mm FNA"

Line 43:45 · 'FNA' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 5: >10 mm FNA,"

Line 44:16 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 5: >10 mm FNA,"

Line 44:45 · 'FNA' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 5: >10 mm FNA,"

Line 44:66 · 'FNA' has no definition. Spell it out if it's unfamiliar to the audience.

"Regardless of US appearance, if the nodule is hot on scintigraphy then the lesion is almost certainly benign and does not require sampling."

Line 46:18 · 'US' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 1: n/a"

Line 49:16 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 2: 0%"

Line 50:16 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 3: low risk (2-4%)"

Line 51:16 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 4: intermediate risk (6-17%)"

Line 52:16 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"EU-TIRADS 5: high risk (26-87%)"

Line 53:16 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"The EU-TIRADS system was published in 2017, following K-TIRADS (2016) and ACR TI-RADS (2017). Other systems including the ATA and SRU are also in regular use."

Line 56:8 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"The EU-TIRADS system was published in 2017, following K-TIRADS (2016) and ACR TI-RADS (2017). Other systems including the ATA and SRU are also in regular use."

Line 56:61 · 'K-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"The EU-TIRADS system was published in 2017, following K-TIRADS (2016) and ACR TI-RADS (2017). Other systems including the ATA and SRU are also in regular use."

Line 56:88 · 'ACR' has no definition. Spell it out if it's unfamiliar to the audience.

"The EU-TIRADS system was published in 2017, following K-TIRADS (2016) and ACR TI-RADS (2017). Other systems including the ATA and SRU are also in regular use."

Line 56:92 · 'TI-RADS' has no definition. Spell it out if it's unfamiliar to the audience.

"The EU-TIRADS system was published in 2017, following K-TIRADS (2016) and ACR TI-RADS (2017). Other systems including the ATA and SRU are also in regular use."

Line 56:143 · 'ATA' has no definition. Spell it out if it's unfamiliar to the audience.

"The EU-TIRADS system was published in 2017, following K-TIRADS (2016) and ACR TI-RADS (2017). Other systems including the ATA and SRU are also in regular use."

Line 56:158 · 'SRU' has no definition. Spell it out if it's unfamiliar to the audience.

"A number of comparative studies of the systems 4,5 show the EU-TIRADS system has sensitivity 83-86% and specificity 32-79%. The rate of unnecessary FNA was 25%, again the intermediate of the three TIRADS."

Line 57:75 · 'EU-TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.

"A number of comparative studies of the systems 4,5 show the EU-TIRADS system has sensitivity 83-86% and specificity 32-79%. The rate of unnecessary FNA was 25%, again the intermediate of the three TIRADS."

Line 57:163 · 'FNA' has no definition. Spell it out if it's unfamiliar to the audience.

"A number of comparative studies of the systems 4,5 show the EU-TIRADS system has sensitivity 83-86% and specificity 32-79%. The rate of unnecessary FNA was 25%, again the intermediate of the three TIRADS."

Line 57:212 · 'TIRADS' has no definition. Spell it out if it's unfamiliar to the audience.
Headings Valid
warning

Expected headings

  • H1 Usage
  • H1 Classification
  • H1 History and etymology
  • H1 Related pathology
  • H1 See also

"Ultrasound features"

Line 3:1 · "Ultrasound features" is not a recognised heading for this article type.

"Recommendations"

Line 39:1 · "Recommendations" is not a recognised heading for this article type.

"Risk of malignancy"

Line 47:1 · "Risk of malignancy" is not a recognised heading for this article type.

"Comparison with other classification systems"

Line 55:1 · "Comparison with other classification systems" is not a recognised heading for this article type.
Oxford Comma
suggestion

"Assessment of the following features as well as size, location and number of nodules are recommended in the reporting of EU-TIRADS:"

Line 4:52 · Use the Oxford comma in 'size, location and number'.
Links
0
0
0
0
0
0
0
0
0
0
0
0